FormaPath key facts
- Developer of automated tools designed to streamline tissue biopsy handling and lymph node isolation for cancer diagnostics.
- It has raised $3.1M; the latest was Seed Round ($2.9M) in Jun 2025.
- Notable investors include MedTech Innovator, MedTech Angels, Cedars-Sinai Accelerator.
- Status: Privately Held (backing).
Who backs FormaPath
3- ·Watch FormaPath: the Monday email on marks, rounds and moves
FormaPath funding rounds
No funding rounds for FormaPath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
FormaPath investors
3 investors are on record for FormaPath, including MedTech Innovator, MedTech Angels and Cedars-Sinai Accelerator.
About FormaPath
Developer of automated tools designed to streamline tissue biopsy handling and lymph node isolation for cancer diagnostics. The company offers a hands-free system for biopsy processing and an instrument that automatically separates lymph nodes from adipose tissue, enabling pathology labs and cancer research centers to improve diagnostic accuracy and efficiency.
- Sector
- Healthcare
- HQ
- Ithaca, NY, United States
- Founded
- 2016
- Employees
- 8
- Website
- formapath.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
FormaPath doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.